HomeActive Pharmaceutical Ingredients

Active Pharmaceutical Ingredients

Catalog No. Product Name Information
A4022 Gefurulimab (Anti-C5 & Serum Albumin) Gefurulimab is a humanized bispecific VHH antibody targeting both terminal complement protein C5 and albumin, with potential anti-inflammatory and immunomodulatory effects. It inhibits the terminal complement pathway by blocking the cleavage of C5 into C5a and C5b, reducing complement-mediated inflammation and cell lysis. By binding to albumin, gefurulimab increases its half-life, offering a potent and selective inhibition of terminal complement activity, including in the rare R885H C5 polymorphism. MW: 28.99 KD.
A4023 Inbrx-105 (Anti-4-1BB & PD-L1) Inbrx-105 is a recombinant, humanized bispecific antibody targeting programmed death-ligand 1 (PD-L1) and 4-1BB (CD137), with potential checkpoint inhibitory, immunostimulating, and antineoplastic activities. By binding to 4-1BB on activated T lymphocytes and PD-L1 on tumor cells, INBRX-105 enhances T-cell co-stimulation and inhibits PD-L1-mediated T-cell inhibition, potentially leading to reduced tumor growth. INBRX-105 exhibits antitumor efficacy and increased T-cell frequency in patients with solid tumors and in in-vivo. MW: 101.9 KD.
A4024 Kn026 (Anti-HER2(Domain II&Domain IV)) Kn026 is a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2), binding to HER2 domains II and IV. It demonstrates a well-tolerated safety profile and promising anti-tumor efficacy in advanced HER2-positive gastric cancer (GC) and gastroesophageal junction cancer (GEJC). MW: 145.19 KD.
A4026 Talquetamab (Anti-CD3 & GPRC5D) Talquetamab is a bispecific humanized monoclonal antibody targeting human CD3 on T cells and the multiple myeloma-associated antigen G protein-coupled receptor family C group 5 member D (GPRC5D) on tumor cells. It redirects T cells to bind and attack GPRC5D-expressing tumor cells, inducing a potent cytotoxic T-lymphocyte (CTL) response. Talquetamab is approved by the U.S. Food and Drug Administration (FDA) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. MW: 144.6 KD.
A4027 Izalontamab (Anti-EGFR & HER3) Izalontamab is a bispecific IgG antibody that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). It demonstrates significant anti-tumor efficacy and acceptable tolerance in xenograft models of colon cancer, head and neck cancer, and esophageal cancer. MW: 197.22 KD.
A4028 Mgd010 (Anti-CD79b & CD32b) Mgd010 is a bispecific dual-affinity retargeting (DART®) molecule that targets both the B cell surface proteins CD32B and CD79B, delivering a co-inhibitory signal to dampen B cell activation. It holds potential for treating autoimmune diseases such as rheumatoid arthritis and other inflammatory conditions. MW: 108.77 KD.
A4029 Teclistamab (Anti-BCMA & CD3) Teclistamab is a humanized bispecific IgG4 monoclonal antibody that targets CD3 on T cells and B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells. It triggers a T cell-mediated immune response, leading to the elimination of BCMA-positive cells and exhibits the potential to treat patients with triple-class exposed relapsed/refractory multiple myeloma (R/RMM). MW: 143.66 KD.
A4030 Alnuctamab (Anti-BCMA & CD3) Alnuctamab is a bispecific T-cell engager (BiTE) antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. It demonstrates encouraging antitumor activity in patients with relapsed or refractory multiple myeloma. MW: 192.35 KD.
A4031 Davutamig (Anti-cMet) Davutamig is a human bispecific IgG4-kappa antibody that binds to two distinct epitopes of MET, blocking ligand binding and inducing MET internalization and degradation. It demonstrates antineoplastic activity. MW: 144.89 KD.
A4032 Emb01 (Anti-cMet & EGFR) Emb01 is a tetravalent, bispecific antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (cMET) on tumor cells, preventing receptor activation and inducing receptor endocytosis, which effectively eliminates these targets on tumor cell surfaces. It demonstrates significant anti-tumor activity in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models, with the potential to treat EGFR antibody-resistant non-small cell lung cancer (NSCLC). MW: 237.9 KD.
A4033 RO7122290 (Anti-4-1BB & FAP) RO7122290 is a bispecific antibody-like fusion protein consisting of a trimeric ligand for the T-cell co-stimulatory immune receptor 4-1BB (CD137) and an antigen-binding fragment (Fab) moiety targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. It exhibits potential for treating advanced solid tumors. MW: 177.78 KD.
A4034 Gen1042 (Anti-4-1BB & CD40) Gen1042 is a bispecific antibody that targets and conditional stimulates CD40 and 4-1BB to enhance the priming and reactivation of tumor-specific immunity in patients with cancer. It enhances antitumor immunity by modulating DC and T-cell functions and exhibits biological activity in patients with advanced solid tumors. MW: 145.37 KD.
A4035 Hpn536 (Anti-CD3e & Mesothelin & Serum Albumin) Hpn536 is a tri-specific, T-cell–activating protein-based construct that binds to mesothelin (MSLN)-expressing tumor cells and CD3ϵ on T cells, leading to T-cell activation and potent redirected target cell lysis. It also binds to serum albumin, extending its plasma half-life. HPN536 demonstrates extended half-life in nonhuman primates (NHP) and has the potential to treat mesothelin-expressing solid tumors. MW: 52.92 KD.
A4036 Gen3009 (Anti-CD37) Gen3009 is a bispecific IgG1 antibody targeting two non-overlapping epitopes on CD37 (biparatopic) with an E430G hexamerization-enhancing mutation. It exhibits significant anti-tumor efficacy in vivo in human cell line- and patient-derived xenograft models, with the potential to treat human B-cell malignancies. MW: 145.37 KD.
A4037 Gen1044 (Anti-CD3 & TPBG) Gen1044 is an anti-CD3/anti-5T4 bispecific antibody, targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating, antineoplastic and antitumor activities. MW: 145.22 kDa.
A4038 Regn7075 (Anti-CD28 & EGFR) Regn7075 is a first-in-class costimulatory bispecific antibody (bsAb), aims to restore immune sensitivity in traditionally non-immunoresponsive tumors by bridging CD28+ T cells with EGFR-expressing tumor cells. It can enhance immune response and anti-tumor immunity. M.W 145.24 kDa.
A4039 Yh32367 (Anti-4-1BB & HER2) Yh32367 is a humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9). It exhibits potential immunostimulating and antineoplastic activities. M.W 200.52 kDa.
A4040 Emb-06 (Anti-BCMA & CD3) Emb-06 is a tetravalent CD3 × BCMA bispecific antibody in a Fabs-In-Tandem-Ig format with four active antigen-binding sites. It targets BCMA on tumor cells and CD3 on T cells, promoting immune activation and antitumor activity. M.W 241.36 kDa.
A4041 Ngm707 (Anti-LILRB2 & LILRB4) Ngm707 is a humanized monoclonal antibody that dual antagonizes ILT2 and ILT4, key inhibitory immune checkpoint receptors. It has potential immunomodulatory and antitumor effects, used alone or in combination for advanced solid tumors. M.W 148.32 kDa.
A4042 Ibi-334 (Anti-B7-H3 & EGFR) Ibi-334 is an ADCC-enhanced bispecific antibody targeting B7-H3 and EGFR, showing potent preclinical efficacy in solid tumors. It blocks EGFR signaling while utilizing a finely tuned B7-H3 arm to enhance inhibition. M.W 145.58 kDa.